Journal
ALLERGY
Volume 76, Issue 6, Pages 1624-1628Publisher
WILEY
DOI: 10.1111/all.14726
Keywords
anaphylaxis; BNT162b2; COVID; mRNA; SARS-CoV; severe allergic reactions; vaccines; virus
Categories
Ask authors/readers for more resources
In response to severe anaphylaxis cases following the COVID-19 vaccine BNT162b2, the EAACI has issued preliminary recommendations emphasizing the importance of understanding severe allergic reactions and not excluding mild to moderate allergic patients from vaccination. Healthcare practitioners must be adequately prepared to recognize and treat anaphylaxis, and a mandatory observation period post-vaccination is recommended.
Further to the approval of the Coronavirus disease 2019 (COVID-19) vaccine BNT162b2, several severe anaphylaxis cases occured within the first few days of public vaccination. An investigation is taking place to understand the cases and their triggers. The vaccine will be administered to a large number of individuals worldwide and there are raising concerns that severe adverse events might occur. With the current information, the European Academy of Allergy and Clinical Immunology (EAACI) states its position for the following preliminary recommendations that are to be revised as soon as more data emerge. To minimize the risk of severe allergic reactions in vaccinated individuals, it is urgently required to understand the specific nature of the reported severe allergic reactions, including the background medical history of the individuals affected and the mechanisms involved. To achieve this goal, all clinical and laboratory information should be collected and reported. Mild and moderate allergic patients should not be excluded from the vaccine as this could have a significant impact on reaching the goal of population immunity. Healthcare practitioners vaccinating against COVID-19 are required to be sufficiently prepared to recognize and treat anaphylaxis properly with the ability to administer adrenaline. Further to vaccine administration, a mandatory observation period of at least 15 minutes should be followed for all individuals. The current data have not shown any higher risk for patients suffering from allergic rhinitis or asthma, and this message should be clearly stated by physicians to enable our patients to trust the vaccine. More than 30% of the population suffers from allergic diseases and the benefit of the vaccination clearly outweighs the risk of severe COVID-19 development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available